Studies of reprogramming of cardiac metabolism involving HIF-1? and PPAR? activation will provide important new information that can potentially lead to the development of therapeutic tools for cardiovascular diseases such as hypertension, myocardial infarction, valvular heart disease and genetic mutations. Because cardiac hypertrophy has been considered as an important risk factor for cardiac morbidity and mortality whose prevalence has increased during last few decades, this study has the potential to directly address improved human health outcomes.
The goal of this proposal is to evaluate the contributions of HIF-1? and PPAR? activation before, during, and after pregnancy to substrate metabolism in the left ventricle. The specific aims will address the central hypothesis that HIF-1? and PPAR? activation coordinate the reprogramming of cardiac metabolism during pregnancy, and that the HIF-1? and PPAR? activation is reversible during postpartum to coordinate the cellular metabolic response against hypertrophy.
Nature of the project
Scope of impact
Type of cooperation with other institutions
Type of financing
Type of research
Area of knowledge
CIENCIAS DE LA VIDA
CIENCIA Y TECNOLOGÍA
|Effective start/end date||1/07/14 → 31/12/15|